Philippines May Receive Up to 7 Million Vaccine Doses This Month
(Bloomberg) -- The Philippines' coronavirus inoculation drive could leap this month, with the possibility of increasing vaccine supplies to about seven million shots from four million. That may boost bids to further reopen.
Between one million to two million AstraZeneca Plc.'s vaccine doses and 1.3 million Pfizer-BioNTech's shots could be delivered this month through the World Health Organization's Covax facility, Carlito Galvez, the nation's vaccine czar, said in a taped briefing televised late Wednesday. “We could get good volumes this May,” he said.
On Monday, Galvez said the nation expects delivery in May of about 4 million doses of vaccines developed by China's Sinovac Biotech Ltd. and Russia's Gamaleya National Center of Epidemiology and Microbiology.
The Philippines is counting on vaccines to help reopen an economy struggling to rebound from last year's record slump. The government is seeking doses from various nations and manufacturers amid possible delays in delivery of shots from India, which is facing its worst outbreak to date.
As of Tuesday, the government has inoculated about 2.07 million, with 1.7 million at their first dose, Galvez said. In June, the nation's vaccine supply will be boosted by shots from Moderna Inc., he said.
Get More:
- In the same briefing, President Rodrigo Duterte said he was “warned” by Chinese President Xi Jinping not to create “trouble” during one of their face-to-face meetings. Duterte said the warning came after he told Xi that “some” day he will stake the Southeast Asian nation's claim in the disputed South China Sea
- Duterte also said he's ordered withdrawal of 1,000 shots of Sinopharm Group Co. Ltd.'s vaccine to quell criticism. He earlier this week took a Sinopharm vaccine even though the local Food and Drug Administration has yet to approve it for emergency use
- Science and Technology Secretary Fortunato de la Peña said the nation's conducting seven trials for possible Covid-19 treatment and prevention including use of anti-parasitic drug ivermectin, virgin coconut oil, lagundi and tawa tawa
- Duterte said the government shouldn't allow people to choose vaccines supplied by the state for this is discriminatory and may create problems
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.